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ABSTRACT
Chronic neurodegenerative diseases of the CNS (central
nervous system) are characterized by the loss of neurons.
There is, however, growing evidence to show that an early
stage of this process involves degeneration of presynaptic
terminals prior to the loss of the cell body. Synaptic plas-
ticity in CNS pathology has been associated with microglia
and the phenomenon of synaptic stripping. We review here
the evidence for the involvement of microglia in synaptic
stripping and synapse degeneration and we conclude that
this is a case of guilt by association. In disease models
of chronic neurodegeneration, there is no evidence that
microglia play an active role in either synaptic stripping or
synapse degeneration, but the degeneration of the synapse
and the envelopment of a degenerating terminal appears
to be a neuron autonomous event. We highlight here some
of the gaps in our understanding of synapse degeneration
in chronic neurodegenerative disease.
Key words: synapse, degeneration, microglia, synaptic
stripping, chronic neurodegeneration.
INTRODUCTION
The focus of much research into pathological processes
underlying both acute and chronic neurodegenerative disease
has been on the factors that trigger death of the neuronal
cell body and the mode of cell death (Friedlander, 2003;
Saxena and Caroni, 2007). However, it is likely that by the
time the cell body enters a phase of recognizable degenera-
tion, be it by apoptosis or other processes, the pathology is
far advanced and the neuron beyond salvage. It seems
unlikely that inhibiting the death of the cell body, which may
only take a number of hours or days, is a practical or useful
proposition in a chronic degenerative disease that might have
progressed over a period of years or even decades. Recently,
there has been a shift in emphasis in this debate to determine
the earliest events in these diseases: it is thought that this
may allow interventions to protect the nervous system from
the ravages of degenerative disease. There is evidence that
degeneration of synapses is one of the earliest pathological
features in several chronic neurodegenerative diseases prior
to the subsequent loss of neuronal cell bodies. It is unclear,
however, whether the degenerative disease process is an
incremental sequence in which there is synaptic dysfunction,
synaptic degeneration followed by degeneration of the cell
soma, with early synaptic events occurring independently
of communication with the cell body, or whether there is
continual simultaneous degeneration-related communication
between the different compartments of the neuron.
It is also well known that non-neuronal cells of the CNS
(central nervous system) play an intimate role in synaptic
communication and that processes of astrocytes are well
placed to influence synaptic transmission and survival. The
so-called tripartite synapse, which comprises pre- and post-
synaptic elements and an astrocytic process, demonstrates
the intimate relationship of astrocytes and synapses (Perea
et al., 2009). The resident macrophages of the CNS, the
microglia, have long been implicated in synaptic remodelling
in the adult brain. Recent evidence suggests that microglia
may selectively contact synapses in their vicinity (Wake et al.,
2009) and, unlike astrocytes, these cells make dynamic
contacts with the synaptic subcompartment of the neuron.
The intimate interactions between microglia and synapses
have been hypothesized to bring about the so-called synaptic
stripping (Blinzinger and Kreutzberg, 1968), a process in
which microglia selectively remove synapses from injured
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neurons. We discuss here what is known about the process of
synaptic degeneration in the CNS and focus on whether there
is evidence that microglia precipitate or participate in this
process.
MICROGLIA
Microglia, the resident macrophages of the CNS, are distinct
from other tissue macrophage populations on account of their
unusual morphology and phenotype, commonly referred to as
down regulated or quiescent (Ransohoff and Perry, 2009). The
CNS microenvironment has a profound effect in regulating
the phenotype of microglia and in recent years some of these
molecular interactions have been elucidated. There is a growing
list of molecules expressed or secreted by neurons that bind
to receptors on microglia. For example, CD200 expressed on
neurons binds to the CD200R receptor on microglia, a receptor
that contains an ITIM (inhibitory tyrosine immunomodulatory
motif). This motif initiates a signalling cascade in macrophages
that leads, in turn, to down-regulation of the state of activation
of the macrophage (Barclay et al., 2002). In mice lacking CD200,
microglia show evidence of being morphologically activated,
and these mice are prone to a more rapid onset of clinical symp-
toms in EAE (experimental allergic encephalomyelitis) (Hoek
et al., 2000). CX3CL1 is an example of a molecule expressed and
secreted by neurons that regulates the microglia phenotype
(Ransohoff and Perry, 2009). The importance of neurons, and
likely also astrocytes, in controlling the microglia level of
activation is critical to understanding changes in the microglia
phenotype in neurodegenerative disease. The demise of the
neuron or its processes will lead to loss of regulation of
the microglia phenotype, unless of course there are adaptive
changes in the expression of either ligands or their receptors.
Microglia monitor the microenvironment
Although the microglia have commonly been described as
down regulated, quiescent or resting, in keeping with their role
as players in host defence, these cells continually survey their
local microenvironment. Elegant in vivo imaging studies with
two-photon confocal microscopy show that fluorescently
labelled microglia continually move their fine processes so as
to palpate or sample the surface of cells and interstitial fluid
in their immediate vicinity (Davalos et al., 2005; Nimmerjahn
et al., 2005). Within a few hours, the microglia processes will
effectively make contact with the entirety of surfaces that lie
within their territory. The microglia rapidly respond to the
presence of a small focal laser lesion in the brain parenchyma
and orient their processes towards the tissue damage (Davalos
et al., 2005). The sensing of tissue damage by the microglia
involves the purinergic receptors and these and other
neurotransmitter receptors play a critical role in modulating
microglia functions (Hanisch and Kettenmann, 2007).
Using mice that express both fluorescently labelled
microglia and cortical pyramidal cells, it has been demon-
strated that microglia make contact with synapses within
their territory with a frequency of about once per hour, and
the time of this contact is of the order of 5 min (Wake et al.,
2009). The significance of these transient contacts with
synapses is not clear but the release of molecules such as
glutamate and ATP may modify these dynamic contacts
(Hanisch and Kettenmann, 2007). Reducing synaptic activity
in the visual cortex, either by removal of the sensory input or
the use of tetrodotoxin, has an impact on the frequency of
microglia contacts with synapses, reducing it to about one-
third (Wake et al., 2009). On the other hand, microglia make
extended contacts with synapses in the penumbra of an
ischaemic lesion. These observations are consistent with the
microglia playing a role in synaptic homoeostasis and in
synaptic pathology, but the extent to which these physical or
chemical contacts are necessary or sufficient for synaptic
dysfunction, degeneration and loss is not yet established.
Microglia in development
In the developing CNS, it has been shown that microglia play
a role in the removal of cells undergoing apoptosis (Perry
et al., 1985) and there is evidence from studies of slice
cultures that microglia play an active role in the killing of
supernumerary Purkinje cells (Marin-Teva et al., 2004). It has
recently been suggested that microglia may also be involved
in the removal of supernumerary synapses. Stevens et al.
(2007) showed that mice lacking complement components
C1q and C3 have deficits in developmental synaptic refinement
in the visual system. They propose that C1q labels synapses that
are destined to be removed and speculate that since microglia
express receptors for complement components they may be
involved in this process. As discussed elsewhere (Perry and
O’Connor, 2008), it is at present unclear how a soluble protein
such as C1q targets particular synapses, and the lack of
involvement of microglia in synaptic stripping in pathology
(see below) suggests that more needs to be done before
concluding that microglia have a role in refining synaptic
connectivity in development. The PU.1 mouse, which lacks
microglia (McKercher et al., 1996), offers a way of addressing
this issue. Even though the animals die a few weeks post-
natally, they survive the period in which microglia have been
implicated in synaptic refinement (Stevens et al., 2007).
Microglia and synaptic stripping
The classic work of Kreutzberg and colleagues demon-
strated the exquisite sensitivity of microglia to disturbances
of homoeostasis (Kreutzberg, 1996) and the value of the
facial nerve transection model for the study of glia reactivity
in the CNS in response to a peripheral nerve injury (see Moran
and Graeber, 2004 for references). It was from the study of
this model that the concept of microglia involvement in
’synaptic stripping’ evolved (Blinzinger and Kreutzberg, 1968).
VH Perry and V O’Connor
282 E 2010 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
Injury to the facial nerve results in a reaction of the motor
neuron cell body and the retraction and loss of synaptic
boutons from the surface of the cell body and proximal
dendrites. The cell body response to injury is accompanied by
the rapid proliferation of microglia, which then enwrap the
cell body with their processes. These observations led to
the suggestion that the microglia might be involved in the
active removal or ’stripping’ of these synaptic contacts. Similar
observations on synaptic stripping have been made after injury
to the hypoglossal nerve and during inflammation in the
cortex (Svensson et al., 1993; Trapp et al., 2007). It is important
to note that in the facial nucleus there is no evidence that the
microglia are actually phagocytosing or digesting the synapses,
it rather may be simply guilt by association. The fine microglia
processes are interposed between the presynaptic element and
the postsynaptic cell soma, with microglia processes encircling
an apparently healthy presynaptic element (see Figure 2;
Moran and Graeber, 2004).
To address whether the microglia are actively involved in
the removal of motor neuron somatic synaptic contacts after
peripheral nerve injury several groups have manipulated
microglia proliferation. Inhibition of injury-induced microglia
proliferation by the application of intraventricular cytosine
arabinoside (Ara C), after transection of the hypoglossal
nerve, had no impact on the retraction of synapses from the
motor neuron cell body and, importantly, this treatment had
no discernable impact on the subsequent success of regene-
ration of the peripheral nerve (Svensson and Aldskogius, 1993).
Similarly, studies in the op/op mice, a strain that lacks
functional macrophage CSF-1 (colony stimulating factor-1),
showed that in the absence of this growth factor, although
microglia do not proliferate after peripheral nerve transection,
synaptic withdrawal or removal still takes place (Kalla et al.,
2001). These studies show that microglia proliferation is not an
essential process in the remodelling or withdrawal of
presynaptic contacts from an injured neuron of the adult
CNS; synaptic pathology induced plasticity proceeds without
microglia synaptic stripping.
In the facial nerve model, the lesion occurs distal to the
synaptic contact and thus a signal must pass from the lesion
to the neuronal cell soma and subsequently to the pre-
synaptic contacts to initiate the synaptic withdrawal
response. The signals from the lesion site to the motor nerve
cell body, the signals that initiate chromatolysis, have been
described recently and involve both a rapid electrophysio-
logical and an importin-mediated injury signal (Rishal and
Fainzilber, 2010): these signals activate intrinsic regeneration
and repair programmes. Whether importins are involved in the
rapid up-regulation of nNOS (neuronal-nitric oxide synthase)
activity following nerve injury is unclear (Yu, 2002). However,
the time course of expression of nNOS is co-extensive with the
period of synaptic withdrawal from the cell body (Sunico et al.,
2005) and pharmacological manipulation of nNOS shows that
in the absence of NO presynaptic withdrawal is arrested. It
was also demonstrated that the up-regulation of nNOS was
associated with S-nitrosylation of elements adjacent to
the injured neuronal cell bodies. The authors speculate that
changes in trophic factor expression, well documented in the
injured facial nerve lesion model (Moran and Graeber, 2004),
have a role to play in conjunction with changes in NO levels
(Sunico et al., 2005). However, this group’s recent work shows
that NO leads to the phosphorylation of the myosin light chain,
part of a cascade known to cause neurite retraction, and is
therefore well suited to the synapse withdrawal process
(Sunico et al., 2010). The role of NO as a retrograde messenger
for synaptic withdrawal conceptually parallels studies dem-
onstrating a role for NO and other retrograde signalling
molecules in modifying synaptic efficacy in the LTP (long-term
potentiation) paradigm (Garthwaite, 2008).
The evidence described strongly suggests that synaptic
withdrawal from motor neurons following peripheral nerve
injury is a neuron autonomous event and does not require
active participation of the microglia. It is important to
recognize, however, that in this pathology the synapses are
not actually degenerating but are still part of an intact
healthy presynaptic neuron with the capacity to re-establish
functional connections once the peripheral neuron has
regenerated. We now consider whether synaptic dysfunction
and degeneration in chronic neurodegeneration involves
microglia.
SYNAPSE DEGENERATION
There are important diseases of the CNS that are associated
with the accumulation of misfolded proteins either extra-
cellularly, such as Alzheimer’s disease and prion diseases, or
intracellularly, such as Parkinson’s disease and ALS (amyo-
trophic lateral sclerosis) (Soto, 2003). A significant risk factor
for many of these chronic neurodegenerative diseases is old
age and with increasing life expectancy their prevalence is
increasing. A major focus of research has been to understand
the processes that link the presence of a misfolded protein
and the degeneration of neurons, with the ultimate aim
of preventing the neuronal degeneration. At present, this
linkage is poorly understood (Aguzzi et al., 2008; Soto, 2003).
Although there is evidence that an early and significant
part of the pathology of these diseases is the dysfunction,
degeneration or loss of synapses (Conforti et al., 2007; Saxena
and Caroni, 2007), the demonstration that a particular
synapse in the CNS becomes dysfunctional or degenerates
prior to either changes in or the demise of the cell body of
origin is not a simple matter; this is true of neuron
populations in both the human brain and in experimental
models. In Alzheimer’s disease, synaptic degeneration is an
important correlate of the degree of cognitive impairment
(Scheff and Price, 2006) and the loss of dendritic spines from
neurons is well documented. We do not know, however,
precisely where synaptic degeneration was initiated and
whether there are changes in the cell body or the axonal
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transport of essential synaptic components prior to synaptic
changes. The investigation of these early components of
neurodegeneration, be they in the pre- or post-synaptic
elements, is greatly aided by the development of animal
models that simulate at least some components of the human
neurodegenerative disease. The synaptic loss that has been
documented in human neuropathology has been demon-
strated in a number of these models (Table 1). Temporal
investigation of these models is often consistent with a linear
sequence in which the disease causing insult leads to synaptic
dysfunction and loss that precedes eventual neuronal cell loss
(Figure 1A), although alternative pathways to neuronal loss
may also operate (Figure 1B). A simple progression from
synapse dysfunction to degeneration and then cell loss should
not, however, be assumed at the present time in all chronic
neurodegenerative diseases.
A valuable system in which it has been shown that synaptic
degeneration precedes the demise of the cell soma is the
animal models of ALS. In transgenic animals, overexpression
of mutated forms of the enzyme SOD-1 (superoxide
dismutase-1) leads to the death of spinal motor neurons
(Turner and Talbot, 2008). In these mice, the peripheral
synapses in a defined muscle with their cell bodies of origin in
the appropriate spinal cord segment are readily studied and it
has been shown that synapses at the neuromuscular junction
degenerate prior to the cell soma (Frey et al., 2000; Fischer
et al., 2004). However, an elegant analysis of retrogradely
labelled motorneurons demonstrates up-regulation of the ER
(endoplasmic reticulum) stress pathway prior to the loss of
neuromuscular junction synapses and eventual loss of the cell
body (Saxena et al., 2009). Although these biochemical
changes at the cell body are the first outward sign of the
impending demise of the synapse and cell body, microglia
activation precedes even these changes. This paper highlights
the importance of knowing the neuronal cell body of origin
of synapses, which makes it possible to demonstrate cell
body-related changes that may precede both degeneration of
the synapse and morphological changes in the cell body.
Importantly, it remains to be shown whether ER stress
proteins in the neuromuscular junction synapses have also
been up-regulated and, if they are, whether changes in
expression at the synapse precede, follow or coincide with
changes in the cell body.
In the case of protein misfolding, diseases dominated by
the deposition of extracellular aggregates the evidence
suggests a similar sequence of synapse dysfunction then
synapse degeneration followed by neuronal loss. In mouse
models of Alzheimer’s disease that overexpress hAPP (human
amyloid precursor protein) with pro-amyloidogenic point
mutations, or in combination with other genes related to
familial Alzheimer’s disease such as presenilin-1, there are
widespread deposits of amyloid in the brain. Many of these
models show synaptic loss (Table 1), but limited evidence of
neuronal loss, indicating that synaptic degeneration can
precede the loss of the cell soma. The synaptic loss is
associated with both electrophysiological deficits such as a
reduction in LTP and changes in cognitive behaviour (Table 1).
Our own experience has involved prion disease in mice. In
these studies, we initiate degeneration by selectively
introducing the prion agent into the hippocampus and
analyse the evolution of disease pathology associated with
the accumulation of misfolded prion protein. The loss of
Table 1 Human pathology and animal models: the case for compartmentalized neuronal degeneration with chronic neurodegeneration
following a sequential degeneration process or a simultaneous degeneration of all compartments
The evidence for synapse loss and astrocytic/microglia activation in human disease are designated: ++ good evidence; + some evidence;
+/2 conflicting evidence. A similar scoring system is used to indicate whether experimental data support synaptic dysfunction, synaptic
loss and cell loss in selected animal models of indicated human diseases. In cases where animal models have been assayed temporally,
the case for chronic neurodegeneration generating a sequential (Type A) or simultaneous form of degeneration (Type B) is based on the
simplified schema depicted in Figure 1. The key references supporting the tabulated conclusions are indicated.
Human disease Animal models
Disease Synapse loss
Microglial
activation
Synaptic
dysfunction Synaptic loss Neuronal loss Degeneration type
Alzheimer’s
(A-beta)
++
(Masliah and Terry,
1994)
++
(Striet, 2004)
++
(Shankar and Walsh,
2009)
++
(Koffie et al.,
2009)
+/2
(Duyckaerts
et al., 2008)
Type A
Alzheimer’s
(tauopathy)
++
(Mukaetova-Ladinska
et al., 2000)
+/2
(Striet, 2004)
++
(Polydoro et al.,
2009)
++
(Thies and
Mandelkow,
2007)
+/2
(Ding and
Johnson,
2008)
Type A
(Yoshiyama et al.,
2007)
Prion ++
(Clinton et al., 1993)
++
(Eitzen et al.,
1998)
++
(Chiti et al.,
2006)
++
(Jeffrey et al.,
2000)
++
(Gray et al.,
2009)
Type A
(Gray et al.,
2009)
Huntington’s ++
(DiProspero et al.,
2004)
+/2
(Mo¨ller, 2010)
++
(Smith et al.,
2005)
++
(Smith et al.,
2005)
+/2
(Yamada
et al., 2008)
Type A/Type B
Parkinson’s ++
(Schulz-Schaeffer, 2010)
+/2
(Banati et al.,
1998)
++
(Bagetta et al.,
2010)
++
(Helton et al.,
2008)
+/2
(Kahle, 2008)
Type B
(Sulzer, 2007)
Motor neuron
diseases (ALS)
++
(Fischer et al., 2004)
+
(Kawamata et al.,
1992)
++
(Geracitano et al.,
2003)
++
(Pun et al.,
2006)
++
(Pun et al.,
2006)
Type A
(Saxena et al.,
2009)
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synapses has been reported in mouse models of prion disease
prior to the onset of neuronal loss. Electron microscopy
studies show that as many as 25% of the synapses in the
stratum radiatum are lost at a time when there is no
detectable neuronal loss from CA3, the neurons of origin of
the vast majority of these glutamatergic synapses (Jeffrey
et al., 2000; Siskova et al., 2009). The loss of synapses is
proposed as the substrate of behavioural deficits at early
stages of disease (Cunningham et al., 2003), but it is unclear
whether the defects in either behaviour or LTP (Chiti et al.,
2006) can be accounted for by synaptic dysfunction prior to
synaptic degeneration.
Morphology of synaptic degeneration
Although there are numerous reports documenting synaptic
loss in particular brain regions during chronic neurodegen-
erative disease, what we know about the degeneration
process per se and the events that initiate it is much more
limited. A significant change in thinking about synaptic
degeneration has come about from the discovery of the Wlds
mouse (Lunn et al., 1989; Mack et al., 2001). Transection of
an axon in either the PNS (peripheral nervous system) or CNS
leads to the rapid degeneration of the distal synapses and the
axon, Wallerian degeneration. In the Wlds mouse Wallerian
degeneration of synapses and axons in both the PNS and CNS
is dramatically delayed although, as in wild-type mice,
CNS Wallerian degeneration and loss of the ability of axons
to conduct action potentials is slower than in the PNS (Lunn
et al., 1989; Perry et al., 1991). Prior to the discovery of
this mouse, there was little reason to believe that the
degeneration of the axon and synapses was anything other
than the passive degeneration of processes isolated from
the cell soma, their source of support. The discovery that the
chimaeric Wlds protein, which arose as a spontaneous
mutation in a substrain of C57BL mice, leads to dramatic
slowing of Wallerian degeneration (Mack et al., 2001), implies
that in wild-type animals there must be biochemical
Figure 1 Schemes to illustrate the temporal relationship between the presence of an accumulating neurotoxic misfolded protein and the
sequence of events leading to neuronal loss in chronic neurodegeneration
(A) The sequential model. The disease-associated neurotoxic agent (e.g. a misfolded protein) has an impact on neurons that first
causes synaptic dysfunction, illustrated here by disrupted synaptic vesicle integrity. This disruption progresses through to synaptic
loss in which the synaptic subcompartments and intracellular organelles disappear and in turn compromise the survival of the
remaining neuronal structure. The fragmentation of the axon is illustrated, but similar disintegration has been noted in dendritic
processes. The loss of synapses, axon and dendrites progresses to a stage in which the cell soma undergoes necrosis, apoptosis or
other form of cell loss. Each step, including the neurotoxic insult, synaptic dysfunction, synaptic degeneration and cell loss, has the
potential to produce signalling molecules that lead to the activation of microglia: activation of microglia may in turn lead to
the synthesis of neurotoxic molecules by the microglia. This two-way interaction is indicated by the double-headed arrows. (B) The
simultaneous model. The neurotoxic agent simultaneously impacts on all compartments of the neuron, leading to signalling
dysfunction or failure due to simultaneous effects on the synapse, the axon and cell body. The simultaneous injury of all these
compartments is most easily visualized as the loss of the cell soma. Activation of microglia by either the misfolded protein or the
injured neuron may in turn lead to the synthesis of neurotoxic molecules by the microglia. This two-way interaction is indicated by
the double-headed arrows. Few studies have carried out the detailed temporal investigations that allow these distinct possibilities to
be directly addressed. Further, it should be noted that reality may lie some where between these two extremes.
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processes to both activate and inhibit the axon and synapse
degeneration pathways. The current concept of a neuron with
distinct compartmentalized degeneration has been reviewed
elsewhere (Gillingwater and Ribchester, 2001) and the
molecular basis of the mode of action of Wlds is being hotly
pursued (Coleman and Freeman, 2010). If synapse degenera-
tion is an active process, it is critical to understand the
sequence of events involved.
In the PNS, when synapses at the neuromuscular junction
undergo Wallerian degeneration, there is a withdrawal of the
presynaptic ending from the postsynaptic sites, with pre-
servation of both the presynaptic membrane and the synaptic
vesicles (Winlow and Usherwood, 1975). Detailed analysis
of the degeneration process is facilitated in Wlds mice with
slowed degeneration, and electron microscopy studies show
that withdrawal of the presynaptic terminal is associated with
retention of synaptic vesicle content, invasion of the terminal
by neurofilaments and envelopment of terminal fragments by
Schwann cells (Gillingwater et al., 2003). The retraction of the
synapse during PNS Wallerian degeneration has clear parallels
with modelling of the neuromuscular junction synapse in
development. The retracting synapses shed small organelle-
rich membrane-bound portions of the axon, so-called
axosomes, which are engulfed by Schwann cells (Bishop
et al., 2004). Lysosomes in the withdrawing axon and the
Schwann cell have been described and are likely involved in
degrading the terminal (Song et al., 2008).
In contrast to the PNS, during Wallerian degeneration in
the CNS, degenerating synapses do not withdraw from the
PSD (postsynaptic density). The presynaptic terminal has
electron dense cytoplasm with the apparent loss of integrity
of synaptic vesicles and other organelles, but the presynaptic
membrane remains intact and closely adhering to the
PSD membrane (Lund and Lund, 1971; Nadler et al., 1980).
Studies of Wallerian degeneration in the corticostriatal
pathway in both wild-type and Wlds mice show that the
morphology of the degeneration process is identical, although
delayed, in the Wlds mice (Gillingwater et al., 2006). In a small
number of instances, the portion of the axon immediately pre-
terminal to the degenerating synapse was morphologically
intact, consistent with the idea that degeneration of the
synapse is indeed a compartment-specific event.
It is clear from the available data that degeneration of CNS
synapses induced by an acute injury is distinct from that seen
in the PNS at the neuromuscular junction. During acute
degeneration of synaptic terminals in the PNS there is
involvement of the Schwann cells that phagocytose some of
the degenerating material, while in the CNS there is little
evidence of direct involvement of either the microglia or
astrocytes. Despite their lack of involvement in synapse
phagocytosis, microglia rapidly respond to the presence of
synaptic degeneration with increased or de novo expression
of different proteins and a change in morphology (Rao and
Lund, 1993; Jensen et al., 1999). The nature of signals from
degenerating synapses that lead to activation of the
microglia are not known although there are many potential
candidates including neurotransmitters and other low-
molecular mass mediators (Hanisch and Kettenmann, 2007).
While the activation of microglia and the subsequent
degeneration of synapses are coincident in time and space,
the association may not be a causative one.
Synaptic degeneration in chronic
neurodegeneration
In chronic neurodegenerative diseases in humans, the study of
synapse degeneration is limited by the availability of tissue with
the appropriate tissue fixation and preservation. Animal models
of protein misfolding disease offer an opportunity to study
these events, in particular, in circuits where the cell body of
origin is well defined. Prion disease in mice is a highly tractable
laboratory model of chronic neurodegeneration caused by the
presence of a misfolded protein (Aguzzi et al., 2008). Unlike
many other models, the precise timing and locus of the site of
initiation of disease is under the control of the experimenter.
The appearance of the first behavioural deficit in the ME7 prion
model appears in hippocampal-dependent tasks (Guenther
et al., 2001) and, since the circuitry of the hippocampus is well
known, this offers the opportunity to dissect the anatomical
and electrophysiological substrate of these behavioural deficits.
At the time of appearance of the first behavioural deficit there
Figure 2 Electron micrographs to illustrate synapse degeneration in the
stratum radiatum of a mouse affected by prion disease
(A) The image shows a normal symmetric synapse with well-defined individual
vesicles (arrowhead) (a), while in degenerating synapses (b and c) the cytoplasm
is electron dense and the integrity of the synaptic vesicles is lost. (B–D) Images
of degenerating synapses with varying degrees of envelopment of the dark
degenerating presynaptic compartment by the PSD of the dendritic spine. Note
that in (B) it is possible to resolve the outlines of some vesicles (arrowhead), but
this is lost in (C) and (D). Scale bar in A5500 nm.
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is no loss of neuronal cell bodies, but there is significant loss of
synapses from the stratum radiatum of the hippocampus, as
detected by synaptophysin immunocytochemistry (Cunningham
et al., 2003). The axons of the CA3 pyramidal cells form en
passant synapses on the CA1 pyramidal cells and the varicosities,
presumed synapses, are aligned like a string of beads along the
axon. The cell bodies of origin of these synapses, the CA3
pyramidal cells, do not degenerate during the course of the
disease, but during late stages of the disease they shrink and
show abnormal vacuolation of their dendrites (Belichenko et al.,
2000; Gray et al., 2009). Quantitative electron microscopy studies
have confirmed the loss of the synapses (Jeffrey et al., 2000;
Siskova et al., 2009) and allow a study of the morphological
events.
The degenerating synapses are recognized by the presence
of an electron dense cytoplasm, and the loss of definition of
the vesicle integrity (Figure 2) (Siskova et al., 2009). The
appearance of the presynaptic element is very similar to that
seen in Wallerian degeneration but with a notable difference.
In the animals with prion disease, the presynaptic membrane
not only remains intact in close apposition with the PSD, but
now the PSD also appears progressively curved around the
degenerating presynaptic element (Figures 2A–2D) and, in
advanced stages, it appears that the PSD has almost
completely enveloped the degenerating terminal (Figures 2A
and 2C). The progressive darkening of the presynaptic terminal
has also been reported in hAPP transgenic mice and there is
a notable increase in dark organelles that may be either
lysosomes or autophagic vacuoles (Adalbert et al., 2009). This is
in contrast to the presynaptic endings seen in prion disease and
also in Wallerian degeneration, where there is no apparent
increase in lysosomes or autophagic vacuoles. We should also
be cautious about drawing too close a parallel between synapse
degeneration in Wallerian degeneration and degeneration
mediated by accumulation of an extracellular misfolded protein.
Wlds mice do not show prolonged survival when challenged with
prion disease (Gultner et al., 2009; VH Perry, H Scott and D Boche,
unpublished results).
Perhaps the most striking feature of the prion-induced
synaptic pathology is the increased curvature of the PSD. This
is a remarkable morphological change that requires profound
remodelling of the proteinaceous cytomatrix structure that
acts as an organizer of postsynaptic signalling and is the core
of the transynaptic process that ensures the tight junction-
like association of the pre- and post-synaptic specialization. It
is clear that the PSD structure is susceptible to changes in the
biochemical composition that impact on plasticity. The idea
that the pathological plasticity represents a biologically
relevant pathway is reinforced by observations highlighting
similar morphological changes in PSDs in hippocampal
synapses following the induction of LTP (Connor et al., 2006)
and also during reactive synaptogenesis (Marrone et al., 2004).
It is suggested that the change in curvature is a compensatory
mechanism by which the probability of transmitter release is
increased to improve synaptic efficacy (see Marrone et al.,
2004 for references).
The presence of degenerating synapses enveloped by the
dendritic spine raises a number of interesting questions such
as what happens to the dendritic spine and to the axon. We
have not yet addressed in the prion disease model whether
the degenerating bouton or some of this material is
internalized into the spine or dendrite cytoplasm but there
are precedents for the envelopment of large structures by
neighbouring cells in both pathology and development. Most
remarkable is the process of entosis in which whole cells,
likely cancerous in nature, are engulfed by neighbouring
cells (Overholtzer et al., 2007). In the nervous system, the
envelopment of synapses by the neuronal cell body both in
normal development and following axon injury has been
described (Borke, 1982; Ronnevi, 1979) as has phagocytosis of
diverse materials by neurons (Bowen et al., 2007). In prion
disease, there is a loss of dendritic spines from hippocampal
pyramidal cells, but the relationship with the presynaptic
changes is not established (Belichenko et al., 2000). In vivo
imaging studies of cortical pyramidal cells during prion
disease progression reveal that dendritic spines are retracted
over a period of several days, with the appearance of dendritic
varicosities (Fuhrmann et al., 2007). A further intriguing
question is whether the degeneration of a synapse along the
Schaffer axon leads to the loss of only that synapse or to
the degeneration of the axon distal to the degenerating
synapse as well. Does the spine envelopment compromise the
survival of the distal axon? Studies are in progress to try and
resolve this matter.
Microglia in synaptic degeneration
The electron microscopy studies allow us to address the issue
of whether microglia are involved in the phagocytosis of
degenerating synapses. In the prion model, there is no evidence
at any stage during the envelopment of the synaptic terminal
by the PSD that processes of microglia, or indeed other glia, are
directly involved in the degeneration process (Figures 2A–2D).
Three-dimensional reconstructions from both conventional and
dual-beam electron microscopy rule out the presence of non-
neuronal processes between the presynaptic and postsynaptic
elements (Siskova et al., 2009). In other models of either
Wallerian degeneration in the CNS or chronic degeneration, the
synaptic boutons do not appear to be enveloped by microglia
processes (Adalbert et al., 2009; Scott et al., 2010). The
microglia respond early to the presence of prion pathology in
the hippocampus (Betmouni et al., 1996) and although the
microglia are able to phagocytose latex beads delivered to
the hippocampus of prion-diseased animals (Hughes et al.,
2010) they do not engulf the degenerating synapses.
The microglia in the hippocampus of mice with prion disease
have an activated morphology but are associated with an anti-
inflammatory phenotype, dominated by the presence of
transforming growth factor-beta and prostaglandin-E2, akin
to that seen in macrophages that have phagocytosed apoptotic
cells (Perry et al., 2002; Savill et al., 2002). Given the suggestion
that synapse degeneration is an active compartmentalized
The role of microglia in synaptic stripping and synaptic degeneration
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auto-destructive process (Conforti et al., 2007; Gillingwater
and Ribchester, 2001) one hypothesis would be that this
phenotype arises as a consequence of phagocytosis of the de-
generating synapses. This is clearly incorrect, since the
microglia do not seem to be involved. However, at this stage,
we cannot rule out the possibility that the conspicuous
shrinkage of the presynaptic element is associated with the
shedding of exosomes, nanoparticle-sized membrane vesicles,
which has been described in the PNS (Bishop et al., 2004) and
also for CNS neurons in culture (Faure et al., 2006). It has been
suggested that supernumerary synapses in development and
synapses in neurodegenerative conditions might be opsonized
by complement prior to phagocytosis by microglia (Stevens
et al., 2007). It is unclear whether the complement cascade is
activated or decorates the degenerating synapses in the early
stages of the evolution of prion disease. The possibility that the
slow accumulation of misfolded protease-resistant prion
protein [PrPSc (abnormal disease-specific conformation of
PrP)] activates the microglia is difficult to establish in vivo, but
it is notable that in peripheral tissues, such as the spleen where
PrPSc is also deposited, the local macrophages do not show an
activated phenotype (Cunningham et al., 2005). The factors
that lead to the morphological activation of the microglia with
an anti-inflammatory phenotype are yet to be identified.
Biochemical events in synaptic degeneration
In addition to morphological studies of synapse degeneration,
some attempts have been made to investigate the biochemical
events associated with the morphological changes. Although a
number of studies have shown the loss of synaptic proteins in
late-stage disease in both human and animal models, these are
not particularly informative, since the loss of synaptic proteins
is unsurprising if there is also neuronal degeneration. We have
attempted to address this issue by studying the time points in
prion disease when there is ongoing synaptic loss prior to
detectable neuronal loss. The quantification of the synaptic
proteins from an isolated region of the diseased brain is not
straightforward, since it is not immediately clear what a
particular synaptic protein should be quantified relative to. The
usual housekeeping proteins used in many studies are of little
intrinsic value in a condition where the non-neuronal cells are
dramatically changing in number and changing their proteome
(see Gray et al., 2009 for discussion). We have thus used a
method to quantify the absolute protein loading on Western
blots and then studied both pre- and post-synaptic protein
levels at different stages of disease evolution. A number of
proteins associated with the synaptic vesicle membrane were
the first to show reduced levels of expression, including VAMP-
2 (vesicle-associated membrane protein-2), synaptophysin and
the chaperone CSP (cysteine string protein) (Gray et al., 2009),
and these proteins were also reduced when compared with the
levels of PSD-related proteins. The loss of presynaptic proteins
is consistent with the early morphological changes in which
there is a loss of vesicle integrity but an apparently mor-
phologically intact PSD.
The changes in CSP expression are of particular interest, as
it has been shown that deletion of the CSP gene in mice
(CSP2/2 mice) leads to a synapse degeneration phenotype
and dramatically shortened lifespan of the mice (Fernandez-
Chacon et al., 2004). Whether microglia or astrocytes are
involved in any stage of synaptic degeneration in the
CSP2/2 mice is not known. The degeneration phenotype
of CSP2/2 mice can be rescued by overexpression of the
synaptic protein a-synuclein (Chandra et al., 2005), suggest-
ing an important interaction between these two proteins.
Hence, one might expect that the deletion of this gene would
lead to accelerated synaptic degeneration in chronic
neurodegeneration. A comparison of prion disease progres-
sion by behavioural, biochemical and anatomical methods
surprisingly revealed no difference in disease progression in
mice with or without a-synuclein (Asuni et al., 2010). A
number of in vitro models have interesting parallels with the
loss of presynaptic proteins and the changes in LTP described
in the prion model (Chiti et al., 2006). Parodi and colleagues
(Parodi et al., 2010) have shown that chronic treatment of
neurons with Ab oligomers leads to the loss of presynaptic
proteins and reduced spontaneous activity. In another model,
overexpression of human a-synuclein in hippocampal neu-
rons has a profound effect in down-regulating the expression
of a number of important proteins in synaptic vesicles
including VAMP-2, piccolo and synpasin-1 (Scott et al., 2010).
The authors report abnormally large synaptic vesicles,
suggesting a fusion of vesicle membranes.
At the neuromuscular junction, the Wallerian degeneration
of synapses is not associated with a loss of synaptic vesicles but
there may be a loss of integrity of mitochondria (Gillingwater
et al., 2003). The idea that oxidative stress contributes to
chronic neurodegenerative disease is widespread, but how it
might specifically contribute to degeneration of the synaptic
compartment has not been addressed. We have investigated
whether mitochondria in the hippocampus of prion-diseased
mice with synaptic loss are also affected. We found that
although the mitochondria density remains normal, the
mitochondria show subtle morphological abnormalities and a
reduction in cytochrome c oxidase activity (Siskova et al.,
2010). The change in mitochondrial function is consistent with
magnetic resonance spectroscopy measurements showing a
reduction of the NAA (N-acetylaspartate)/choline and NAA/
creatine ratio in the hippocampus of prion-diseased mice at
the time of synaptic loss (Broom et al., 2007). NAA is widely
accepted as a marker of neuronal functional integrity and is
closely linked with a bio-energetic role in neuronal mitochon-
dria (Moffett et al., 2007). It is at present not clear whether the
mitochondrial changes are a cause or a consequence of the
synaptic degeneration and the events leading to mitochondrial
cytochrome c oxidase impairment are not known. However,
during the period of early synaptic loss and mitochondrial
abnormalities, there is an enhanced expression and activity of
nNOS in the stratum radiatum (Picanco-Diniz et al., 2004). This
could, as discussed earlier, modulate synaptic function and
additionally impair mitochondrial function.
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CONCLUSION
Despite the emerging and obvious importance of synaptic
degeneration in chronic neurodegenerative diseases of the
CNS, it is surprising how little we know about the molecular
events that underlie this process. There is a growing body of
evidence to show that synaptic degeneration takes place
without overt morphological changes at the cell body, but it
remains to be proven that synaptic degeneration takes place
in a truly pre- or post-synaptic compartment-specific fashion
independent of communication from the cell body. It is clear
that at least in some circuits the demise of the presynaptic
element precedes the degeneration of the postsynaptic com-
ponent, but this may not be universal. The degeneration of
synapses in the CNS during both Wallerian degeneration and
during chronic neurodegeneration is distinct from Wallerian
degeneration-induced synapse retraction at the well-studied
peripheral neuromuscular junction. The evidence suggests
that in the CNS, the loss of synaptic vesicle integrity is an
early stage in the degeneration of the presynaptic terminal
and is associated with mitochondrial dysfunction, but there is
little evidence for the direct involvement of microglia and
astrocytes. It is apparent that the degeneration of the
CNS synapse is very different from a simple reversal of
developmental CNS synapse formation where the immature
pre- and post-synaptic partners find each other and establish
an initial contact, which stabilizes and matures if the con-
nection is functionally appropriate (Jin and Garner, 2008). The
synapses that are lost in major neurodegenerative diseases
will have undergone the maturation steps that lead to
the formation of a tightly adherent synaptic specialization.
In view of the functional co-reliance of presynaptic and post-
synaptic components of mature synapses, it is perhaps not
surprising that the degeneration process does not involve the
synaptic elements separating and going their separate ways.
Uncovering the sequence of events involved in the dysfunc-
tion, disassembly and degeneration of these mature CNS
synapses is an important area for future research involving
this fundamental component of chronic neurodegenerative
diseases.
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